Drug discovery company focused on creating novel and patentable psychedelic compounds to treat neurological and psychiatric disorders Mindset Pharma Inc. (CSE: MSET) (OTCMKTS: MSSTF) announced having been issued by a notice of allowance by the United States Patent and Trademark Office (USPTO) titled ‘Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of Central Nervous Disorders (CNS) Disorders.
This patent bears the patent application number 17/387,845 and it enlists several drug candidates belonging to Mindset’s ‘Family 1’ which is second generation compounds with potential improvements compared to psilocybin in pharmacokinetics, effect size, safety, and manufacturing.
Central nervous system diseases better known as disorders, comprises of a set of neurological conditions affecting the structure and /or the functionality of the brain or the spinal cord. The list of such diseases is very wide but some of the most common ones are; autism, addictions and attention-deficit/hyperactivity disorder (ADHD.
“We are very pleased to further reinforce our robust intellectual property portfolio, especially with the advantage of an early priority date of February 2020 for this patent. This is a key step towards continued growth for Mindset and our developing pipeline of drug candidates,” said the company’s CEO, James Lanthier.
Earlier in the year, Mindset had filed another patent application for its underway novel chemical compounds related to DMT and 5-MeO-DMT which falls to its ‘Family 4’ group.
The intention of this new chemical entities being developed is to copy the functionality of first generation psychedelic medicines while optimizing pharmacological and safety profiles for diverse in-clinic needs.